MedDataX Logo

REstore Working Ability in RheumatoiD Arthritis

NCT ID: NCT01405326

Last Updated: 2011-07-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

160 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-05-31

Study Completion Date

2013-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study is to assess whether a 6-month treatment with adalimumab added on the treatment with conventional antirheumatic drugs (DMARD) will decrease the number of days on sick leave compared to placebo. In addition, the cost-effectiveness and cost-utility of the intervention compared to the conventional treatment is evaluated, and the patients who benefit most are characterized.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In spite of the improved medical treatment, rheumatoid arthritis (RA) is still causing both significant morbidity and marked loss of work productivity. Short periods of work inability, i.e., sick leaves represent a significant part of the socioeconomic burden of RA. The study is a randomized, controlled double blind multi-center study. 160 patients of 25 to 55 years of age with recent-onset (≤2 years from diagnosis) RA who have been treated with a combination of conventional antirheumatic drugs but have an inadequate response to treatment and are at the risk of losing their ability to work, are enrolled. The patients should be biologic-naïve. Their RA should be active, but not so active that the conventional criteria for biologic therapy would be fulfilled. The subjects are randomized at 1:1 ratio to receive either adalimumab (40 mg every two weeks) or placebo for 6 months added on their concurrent antirheumatic therapy. The RA-related sickness absence and clinical response will be evaluated.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Rheumatoid Arthritis

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

rheumatoid arthritis biological therapy adalimumab ability to work sick leaves

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Adalimumab

Adalimumab treatment for 6 months

Group Type EXPERIMENTAL

adalimumab

Intervention Type BIOLOGICAL

40mg sc. every two weeks for six months

Pacebo

Corresponding placebo for active treatment group

Group Type PLACEBO_COMPARATOR

adalimumab

Intervention Type BIOLOGICAL

40mg sc. every two weeks for six months

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

adalimumab

40mg sc. every two weeks for six months

Intervention Type BIOLOGICAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Humira

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Diagnosis of RA according to the 1987 revised American College of Rheumatology (ACR) criteria
2. Time from diagnosis of RA \< 2 years
3. Age 25-55 years
4. Active RA with at least 3 active joints (tender and/or swollen joints)
5. Stable DMARD combination treatment for more than 3 months
6. At least one of the following

* Rheumatoid factor positive
* One or more erosions in x-rays of the hands and feet
* Anti-citrulline antibodies positive
7. At least other of the following

* HAQ-index 0.5 or more
* Patient or physician evaluation of RA activity \>25 mm (VAS 0-10 cm)
8. Patient has been steadily in work-life for at least one year and is currently working or on sick- leave but not applying for pension
9. Patient feels that he/she will likely have to be off-work during the following 6 months due to his/her RA
10. Patient must be willing and able to provide written informed consent for the trial
11. Each female subject must agree to use a medically accepted method of contraception while receiving study medication

Exclusion Criteria

1. A subject must not have a history of biological drug use for RA
2. A subject must not have evidence of active or latent tuberculosis,
3. A subject must not have any history of lymphoproliferative disease or malignancy within the previous 5 years
4. A subject must not have any other condition, that according to the investigator's judgment makes him or her non-eligible for anti-TNF use
5. A subject must not have any inflammatory rheumatic disease other than RA
6. A subject must not have received any other investigational agents within 30 days prior to baseline visit, and must not receive them during the current trial
7. A female subject must not be pregnant or breast-feeding or planning pregnancy during the study
8. A subject must not have had a major surgery within one month prior to study entry and must not have a scheduled operation during the 6-month follow up
9. A subject must not have any clinically significant condition or situation, other than the condition being studied, that in the opinion of the investigator would interfere with the optimal participation in the trial.
10. A subject must not fulfill the criteria for reimbursement for biologics for RA and he/she would not normally be prescribed a biological drug according to physicians discretion and national treatment guidelines
11. A patient must not be currently on reimbursed rehabilitation period, or such period must not be scheduled for the next six months
Minimum Eligible Age

25 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Abbott

INDUSTRY

Sponsor Role collaborator

The Rheumatological Center of Helsinki

NETWORK

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

The Rheumatological Center of Helsinki

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Kari K Eklund, MD

Role: PRINCIPAL_INVESTIGATOR

The Rheumatological Center of Helsinki

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Helsinki University Central Hopsital

Helsinki, , Finland

Site Status RECRUITING

Lappland Central Hospital

Rovaniemi, , Finland

Site Status RECRUITING

Tampere University hospital, Rheumatology Centre

Tampere, , Finland

Site Status RECRUITING

The Turku Universitry Central Hopsital

Turku, , Finland

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Finland

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Kari K Eklund, MD

Role: CONTACT

Phone: +358405832866

Email: [email protected]

Kari Puolakka, MD

Role: CONTACT

Phone: +358408354734

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Ritva Peltomaa, MD

Role: primary

Toini Uutela, MD

Role: primary

Heidi Mäkinen, MD

Role: primary

Laura Pirilä, MD

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

RE100002011

Identifier Type: -

Identifier Source: org_study_id